Genetic Engineering & Biotechnology News (GEN) is the world's most widely read biotech publication. It provides the R&D; community with critical information on the tools, technologies, and trends that drive the biotech industry.
Issue link: http://gen.epubxp.com/i/83770
Corporate Capabilities ADVERTORIAL Essen BioScience World Leaders in Live Content Imaging instrumentation experi- ence makes Essen BioSci- ence a unique provider of life science research tools and services. Markets Served Essen BioScience offers powerful solutions for life science researchers in aca- demia, biotech, and phar- maceutical companies throughout the world. The broad applicability of the IncuCyte ZOOM and CellPlayer kinetic assays make them ideal solutions for institutions of all sizes to streamline E Essen BioScience 300 West Morgan Road Ann Arbor, Michigan Phone 734.769.1600 Website www.essenbioscience.com Date Founded 1999 Number of Employees Over 50 ssen BioScience is a world leader in the field of cell-based in vitro assays and instrumentation. In its recent history, Essen has concentrated on imaging products with the release of the IncuCyte™ in 2006, and very recently with the release of the second-generation IncuCyte ZOOM™ in 2012. Along with a comprehensive line of CellPlayer™ kinetic assays and reagents and a renowned global Discovery Services team, Essen BioSci- ence provides quantitative assay solutions in an array of research areas including oncology, neu- roscience, and ion channels. Traditional high-content imaging assays are conducted on live cells, however the assay readout is typically a single predetermined time point. With IncuCyte ZOOM, Essen offers a new type of imaging, Live Content Imaging, where the acquisition, analysis, and quantifica- tion of images are taken from living cells that remain unperturbed by the detection method, allowing for repeated measurements over long periods of time (days to weeks). This approach allows researchers to follow assays in real time, and further does not require the determination of an assay end point a priori. An enabling aspect of the IncuCyte ZOOM technology is that the system acquires images automatically from within the user's cell cul- ture incubator, collecting biological image data around the clock on multiple vessels without removing the cells from their preferred physi- ological environment. The IncuCyte ZOOM is also equipped with integrated software pro- viding real-time analysis of the biological pro- cesses under observation. The IncuCyte ZOOM features multifluorescent colors, support of a broad range of microscope objectives, and en- hanced speed to handle the acquisition and pro- cessing demands of real-time image acquisition and analysis. The CellPlayer reagents include targeted fluorescent probes and fully validated GFP/RFP nuclear labeled stable cell lines. These reagents are nonperturbing to cell health and superior to traditional organic dye labels for long-term imaging assays. Together, the Incu- Cyte ZOOM and suite of CellPlayer assays and reagents provide a fully integrated solution for quantitative, kinetic biology. About the Company Essen BioScience is a privately held company headquartered in Ann Arbor, Michigan with wholly owned subsidiaries in the United King- dom and Japan. Essen has a tradition of inventing break- through technologies for the life science industry including products such as FLIPR, IonWorks, and the IncuCyte fam- ily of Live Content Im- aging systems. To date, these inventions have accounted for approxi- mately one billion dol- lars in worldwide sales. Over the last few years, Essen BioScience has expanded its offerings beyond instrumenta- tion, building a global cell biology team and a range of capabilities including reagent devel- opment, fee-for-service screening, and drug discovery partnerships. The combination of drug discovery and 70 | October 1, 2012 | genengnews.com | Genetic Engineering & Biotechnology News productivity in the lab, get better quanti- tative results from experiments, and make discoveries that were simply impossible with previously existing technology. Capabilities Essen BioScience's inventions have spanned nearly 20 years and are recognized as "first in class" in several technology areas, includ- ing optical cell-based screening (FLIPR, 1994), high-throughput electrophysiology (IonWorks, 2002), and kinetic imaging (IncuCyte, 2006; In- cuCyte ZOOM, 2012). Along with its engineer- ing group and instrumentation offerings, the company's senior staff of biologists possesses strong backgrounds in molecular and cellular bi- ology as well as drug discovery, and is currently engaged in multiple drug discovery outsourcing and partnership projects. Q